iconstar paper   HIV Articles  
Back grey arrow rt.gif
 
 
Ten Things I Learned About Aspirin at ESC 2018, 3 studies on aspirin use COMMENTARY - BOTH STUDIES ARE BELOW
 
 
  Download the PDF
 
Download the PDF
 
Download the PDF
 
Download the PDF
 
COMMENTARY - BOTH STUDIES ARE BELOW
 
John M. Mandrola, MD
August 28, 2018
 
When researchers ask an important question, randomize people into a placebo-controlled trial, and collect and report results, society wins-regardless of the findings. One of the core problems with clinical science is that "positive" studies earn more praise than neutral studies. This is silly because knowing what does not work is as vital as knowing what does work.
 
Now let's talk aspirin (ASA) to prevent cardiac events in people without heart disease. Two major trials presented at the European Society of Cardiology (ESC) Congress 2018 inform this decision. Since millions of people take ASA in hopes of improving health, this is big news.
 
The Trials
 
In ASCEND,[1] more then 15,000 middle-aged patients with diabetes but no evident heart disease were randomized to 100 mg of ASA or placebo. In ARRIVE,[2] more than 12,500 adults with (presumed) moderate risk but no evident heart disease were randomized to 100 mg of ASA or placebo. Both studies used composite primary endpoints of major cardiac events and safety endpoints of bleeding.
 
I spoke with the principal investigators (PIs), Jane Armitage from Oxford University, United Kingdom (ASCEND), and J. Michael Gaziano (ARRIVE) from Brigham and Women's Hospital, Boston, Massachusetts.
 
Ten Take-Away Lessons
 
1. There have been oodles of ASA studies. Why do more?
 
Both PIs explained that there is a knowledge deficit for ASA use in patients at moderate risk. Numerous studies have confirmed ASA's benefit after a cardiac event or intervention-secondary prevention. Fewer studies have addressed primary prevention, and those that did so have included patients at super-low risk. ASCEND and ARRIVE aimed to address the role of ASA for primary prevention in patients with higher cardiac risk. This is a vital question because more and more patients are living with risk factors and moderate risk.
 
2. The top-line results were neutral.
 
In ARRIVE, the intention-to-treat analysis showed no reduction of events with ASA. In ASCEND, the authors came to a "no net benefit" conclusion for ASA because its reduction in cardiac events (about 1.1%) was countered by bleeding events (0.9%).
 
3. Both trials confirmed the biological effect of ASA on reduction of cardiac events.
 
In ASCEND, during an average of 7.4 years of follow-up, ASA reduced the primary endpoint by 12% in relative terms and 1.1% in absolute terms. These findings met statistical significance.
 
The ARRIVE trial was more complex. During an average of 5 years of follow-up, in the intention-to-treat analysis, ASA did not reduce events. Gaziano told me that because of the pragmatic nature of ARRIVE, there were many dropins (controls who started taking ASA) and dropouts (active arm patients who stopped taking ASA). When analyzed according to who actually took ASA, also known as the per protocol analysis, MI rates were significantly reduced, and the 19% relative reduction in the composite primary endpoint nearly met statistical significance (P = .07).
 
4. Both trials confirmed the biological effect of ASA on bleeding.
 
In ASCEND, ASA increased the rate of major bleeding by 29% in relative terms and 0.9% in absolute terms. Most bleeding was from the gastrointestinal (GI) tract. In ARRIVE, ASA doubled the rate of GI bleeding in relative terms but by only 0.5% in absolute terms.
 
5. ASA did not influence severe events.
 
In both trials, ASA had no effect on overall mortality, nor did it increase fatal bleeding.
 
6. Cardiac event rates in ARRIVE were lower than expected.
 
In ARRIVE, the observed rate of cardiac events was only one third of what was expected (550 vs 1488 events). Although the authors tried to enroll higher-risk patients, including only those with multiple risk factors, the cohort ended up being a low-risk group.
 
7. Risk calculators overestimate event rates in western societies.
 
Both Gaziano and Armitage told me that secular trends and increased use of preventive therapies are decreasing cardiac event rates. By secular trends, they mean that societal efforts, such as lower rates of smoking and removal of trans-fats from the food supply, have led to a heart-healthier environment. In addition, greater use of preventive therapies-statins and antihypertensive meds, for instance-have also contributed to lower rates of cardiac disease. These developments increase the difficulty of running trials for primary prevention but are decidedly good news for patients.
 
Gaziano did make the distinction that calculators that use typical risk factors may be more accurate in societies with increasing rates of heart disease, such as China.
 
8. Diabetes is a different disease these days.
 
Armitage told me that in the past, the big fear with diabetes was cardiovascular complications. But in ASCEND, far more deaths resulted from nonvascular causes (61% vs 39%). This, too, is good news, and is likely due to societal trends and better risk factor management.
 
9. No weight-based effects of ASA were seen.
 
A recent post hoc analysis[3] of primary prevention ASA trials provocatively found that low doses of aspirin (75 to 100 mg) were effective only in patients weighing less than 70 kg and had no benefit in the 80% of men and nearly 50% of all women weighing 70 kg or more (about 154 lbs).
 
Neither ASCEND nor ARRIVE found any heterogeneous treatment effect based on weight. Gaziano noted that almost 80% of the ARRIVE participants had a body mass index greater than 25 kg/m2. He said they plan further analyses based on weight. In ASCEND, the trend actually went in the opposite direction: ASA produced a lower rate of events in those heavier than 70 kg. Armitage sternly warned that we should be "very cautious" in the interpretation of post hoc studies.
 
10. ASA had no effects on cancer prevention.
 
In the discussion section of ASCEND, the authors cited multiple meta-analyses of low-dose ASA that suggest a possible reduction in GI cancer with long-term use. And the US Preventive Services Task Force concludes with moderate certainty that the net benefit of aspirin use to decrease colorectal cancer incidence in adults age 50 to 59 years is moderate.
 
The ASCEND trial found no difference in the rate of GI cancer. Gaziano told me they saw no cancer prevention signal in ARRIVE. Both trialists warned that if ASA prevents cancer, the effects would appear after 10 years of use, which is longer than the average follow-up of either study.
 
Conclusion
 
When I asked Armitage what she would recommend to a middle-aged patient with diabetes, she responded that rather than take ASA, it would be better to work hard on risk factor modification. Gaziano echoed the message from their concluding paragraph and said ASA use remains a decision that should involve a thoughtful discussion between a clinician and a patient. His feeling was that avoiding a cardiac event was worth the risk of having a GI bleed.
 
For now, I am closer to Armitage's view: A thoughtful look at ASA use in patients with these risk profiles shows little benefit and little harm. Since people don't have endless reserves of effort, it seems wiser to emphasize more important matters, such as maintaining an ideal weight, seeking physical fitness, taking blood pressure medications, and not smoking.
 
www.natap.org
 
perhaps more interesting is the study in diabetics, coming next. Jules
 
----------------------
 
Full Study article follows below the 2 Commentaries....
 
from 2nd commentary below " Better management of blood pressure, dyslipidaemia, and other risk factors is likely to lower the risk of developing disease, and these interventions are most aggressively used in patients at higher risk.. ARRIVE reflects a contemporary cardiovascular risk prevention (therapy) study in which widespread statin use is the norm. 43% of ARRIVE participants were taking statins. The exclusion of patients with diabetes could also contribute to lower overall risk .........Aspirin also did not show a significant effect on any of the individual components of the primary endpoint.......But daily aspirin was associated with more gastrointestinal bleeding, although such events were few in the study, at less than 1% in either group. The HR was 2.11 (95% CI, 1.36 - 3.28; P = .0007). Hemorrhagic strokes were also rare, with a rate of 0.13% in the aspirin group and 0.18% among controls.,,,,,In prior studies of primary prevention aspirin, many of which were conducted in the 1980s and 1990s, said Gaziano, "when a patient developed angina or a TIA, it wasn't standard practice to put them on aspirin." By the time ARRIVE was conducted, aspirin had become a much more common therapy.
 
"We have much better treatments for atherosclerotic disease now than we had in these old aspirin studies," agreed John G.F. Cleland, MD, Imperial College London, United Kingdom, speaking with theheart.org | Medscape Cardiology.....Cleland, who was not involved with ARRIVE but is an outspoken opponent of aspirin for CV primary prevention, isn't surprised at the low-risk status of the trial participants, who enrolled in an era of "good antihypertensive medications" and widespread statin therapy.
 
"Once you've dealt with the lipids, and once you've dealt with the hypertension, I'm really not sure what's left for aspirin," Cleland said.....One lesson of ARRIVE is that an aspirin recommendation for primary prevention should be based on "a complex calculus involving estimates of cardiovascular risk, potentially cancer risk, and bleeding risk," he said......Even per protocol, aspirin fell short of significance for the composite primary endpoint, at an HR of 0.81 (95% CI, 0.64 - 1.02; P = .076). But there were significant risk reductions for any MI at 0.53 (95% CI, 0.36 - 0.79; P = .0014) and nonfatal of MI 0.55 (95% CI, 0.36 - 0.84; P = .0056)........I'm looking at it for some insights as to why the results are somewhat different from a study we know quite well, the Physicians' Health Study," Gaziano said when interviewed.
 
That study from the 1980s, which randomly assigned more than 22,000 health professionals to aspirin at 325 mg every other day or placebo, famously saw a 44% reduction in risk acute MI (P < .00001)."
 
Comment
 
Aspirin for primary prevention of cardiovascular disease
 
Lancet Aug 26 2018 - *Davide Capodanno, Dominick J Angiolillo
Division of Cardiology, AOU "Policlinico Vittorio Emanuele", PO Rodolico, Catania 95123, Sicily, Italy (DC); and Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA (DJA)
 
The benefit of aspirin for patients with established cardiovascular disease outweighs the risk of bleeding, but the role of aspirin for individuals with no overt cardiovascular disease is more controversial.12
 
In a meta-analysis 3, 4 of 118 445 individuals from 11 trials of aspirin for primary cardiovascular disease prevention, aspirin reduced the relative risk of non-fatal myocardial infarction by 22% and death by 6%, at the cost of a 59% increase in gastrointestinal bleeding and a 33% increase in haemorrhagic stroke. This compromise in bleeding complications has called into question the level of baseline cardiovascular disease risk for which use of aspirin in primary prevention is clinically acceptable. Indeed, in patients at low cardiovascular disease risk, the relative benefit of aspirin translates into marginal absolute benefit, making its use largely unjustifiable. To better define the net benefit of aspirin for primary prevention, four more trials were designed to include individuals at higher cardiovascular disease risk: two of patients with diabetes (ASCEND and ACCEPT-D), one of patients of advanced age (ASPREE), and one of patients at moderate cardiovascular disease risk (ARRIVE; appendix).2 J Michael Gaziano and colleagues5now report the results of ARRIVE in The Lancet.
 
In ARRIVE, 12 546 patients were randomly assigned to receive either low-dose (100 mg) aspirin or placebo tablets once daily, at 501 sites in seven countries. Inclusion criteria included several major cardiovascular disease risk factors, to target a final population at moderate (ie, 20-30%) risk of 10-year cardiovascular disease. Patients with a history of a vascular event or diabetes were excluded. The primary endpoint was a composite outcome of time to first occurrence of cardiovascular death, myocardial infarction, stroke, unstable angina, or transient ischaemic attack, with a median follow-up of 5 years. In the intention-to-treat analysis, there was no significant difference in the primary endpoint, which occurred in 269 (4⋅29%) of patients in the aspirin group and 281 (4⋅48%) of patients in the placebo group (hazard ratio [HR] 0⋅96, 95% CI 0⋅81-1⋅13; p=0⋅6038). There was a lower HR for aspirin in the per-protocol analysis (0⋅81, 0⋅64-1⋅02; p=0⋅0756), paralleled by a significant reduction in fatal or non-fatal myocardial infarction and no effect on mortality. Gastrointestinal bleeding events were mostly mild and approximately two times higher in the aspirin group in the intention-to-treat population (HR 2⋅11, 1⋅36-3⋅28; p=0⋅0007).
 
Some trial aspects are noteworthy and challenge interpretation of the results. The trial was originally designed under the assumption of a projected 13⋅4% event rate in the placebo group. Because of the lower than anticipated event rate, the investigators expanded the initial primary endpoint to include unstable angina and transient ischaemic attack, modified the study design from event-driven to time-driven, and extended the time of observation. Still, the final number of events was considerably lower than anticipated, based on the calculated risk profile of the intended population (550 vs 1488). The investigators acknowledge that a proportion of events might have been undetected because of ascertainment issues. As such, despite the merits of this relatively large randomised, double-blind, placebo-controlled trial and the attempts to enrich the event rates, it ultimately did not address the role of aspirin in patients with at least moderate cardiovascular disease risk, because the study was primarily done with patients at low risk. Also notable is the high number of participants who prematurely terminated the study (approximately a third in both groups). Because crossovers were not tracked and non-compliance to the study allocation was only patient-reported, the results of both the intention-to-treat and per-protocol analyses should be interpreted with caution, particularly in the context of their diverging results and lower than anticipated statistical power.
 
The optimal dosing of aspirin has been a subject of debate.6 Notably, another study published this year, in The Lancet, questions the efficacy of fixed low doses of aspirin for primary prevention in patients of different bodyweight categories. 7 With minimum and maximum bodyweights of 43 kg and 177 kg reported in the placebo group of ARRIVE, whether the same neutral results would be replicated by tailoring the dose of aspirin according to bodyweight remains a matter of interest. Weight-stratified analyses of cardiovascular disease events in the ARRIVE trial are planned. Despite also being designed as one-dose-fits-all trials, important lessons can be learned from two ongoing studies of aspirin for secondary prevention, in which twice-daily versus once-daily (ANDAMAN) and high-dose versus low-dose (ADAPTABLE) strategies are being investigated (appendix). Finally, a key question is whether there is a protective effect of aspirin in cancer prevention (not reported in ARRIVE), for which longer-term follow-up than that reported by the ARRIVE investigators (ie, >10 years) is necessary. 8
 
There are important take-home messages from the ARRIVE trial. First, the overall findings replicate those from previous studies testing the use of aspirin for primary prevention in patients at low cardiovascular disease risk. On the one hand, these study findings reinforce recommendations against the use of aspirin in this setting but, on the other hand, leave unanswered the role of aspirin for primary prevention in patients without diabetes who have at least moderate cardiovascular disease risk. To this extent, the European guidelines do not recommend using antiplatelet therapy in individuals without cardiovascular disease because of the increased risk of major bleeding, 9 whereas the US Preventive Services Task Force advocates initiating aspirin on the basis of age and a 10-year cardiovascular disease risk of at least 10%, as defined by available risk estimators. 10
 
Second, this study highlights the weakness and over-estimation of current methods to define the 10-year risk of cardiovascular disease, which are still based on historical data, underscoring the need for more reliable and contemporary estimates of cardiovascular risk. Finally, the study provides insight into the challenge of doing pragmatic trials of aspirin in an era characterised by other preventive and therapeutic interventions. Overall, the consistent trend in negative results from trials of aspirin in primary prevention, particularly in patients without diabetes, suggests that new avenues of research are needed for the prevention of cardiovascular events.
 
--------------------------------
 
Daily Aspirin Fails to Lower CV Risk in Long-term, Primary Prevention ARRIVE Trial
 
MUNICH - Aspirin at a daily dose of 100 mg was not seen to reduce the long-term risk for cardiovascular (CV) or cerebrovascular events in a trial that randomly assigned more than 12,000 nondiabetic adults with multiple CV risk factors but no history of CV events. Nor was the risk for stroke reduced.
 
In the study's primary intention-to-treat (ITT) analysis, 4.29% of persons assigned to aspirin and 4.48% of those in the placebo group experienced the primary endpoint of CV death, myocardial infarction (MI), unstable angina, stroke, or transient ischemic attack (TIA) over a mean of 5 years. The adjusted hazard ratio (HR) for aspirin vs placebo was 0.96 (95% confidence interval [CI], 0.81 - 1.13; P = .604).
 
Aspirin also did not show a significant effect on any of the individual components of the primary endpoint.
 
But daily aspirin was associated with more gastrointestinal bleeding, although such events were few in the study, at less than 1% in either group. The HR was 2.11 (95% CI, 1.36 - 3.28; P = .0007). Hemorrhagic strokes were also rare, with a rate of 0.13% in the aspirin group and 0.18% among controls.
 
The Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE) trial, initiated a decade ago, sought to answer long-standing questions about whether aspirin is cardioprotective in a primary prevention setting, in this case in patients thought to be at moderate CV risk. As described by J. Michael Gaziano, MD, Brigham and Women's Hospital, Boston, Massachusetts, the lack of aspirin effect likely stems from the trial having entered what turned out to be a lower-risk population than its design anticipated.
 
The trial had aimed to enroll a moderate-risk cohort, and the risk calculators applied to persons who entered the study put their estimated 10-year CV risk at 17.3%. Yet the mean observed 10-year rate of events was less than 9%, Gaziano observed.
 
Moreover, any outcomes difference that might have emerged between the two groups was likely diluted by the dynamic, evolving backdrop of CV therapies throughout the trial, Gaziano told theheart.org | Medscape Cardiology.
 
In prior studies of primary prevention aspirin, many of which were conducted in the 1980s and 1990s, said Gaziano, "when a patient developed angina or a TIA, it wasn't standard practice to put them on aspirin." By the time ARRIVE was conducted, aspirin had become a much more common therapy.
 
"We have much better treatments for atherosclerotic disease now than we had in these old aspirin studies," agreed John G.F. Cleland, MD, Imperial College London, United Kingdom, speaking with theheart.org | Medscape Cardiology.
 
Cleland, who was not involved with ARRIVE but is an outspoken opponent of aspirin for CV primary prevention, isn't surprised at the low-risk status of the trial participants, who enrolled in an era of "good antihypertensive medications" and widespread statin therapy. "Once you've dealt with the lipids, and once you've dealt with the hypertension, I'm really not sure what's left for aspirin," Cleland said.
 
Informing the Dialog
 
In recent years, CV guidelines have emphasized patient predicted risk when recommending medical therapies, such as statins or blood pressure-lowering drugs, Gaziano pointed out. One lesson of ARRIVE is that an aspirin recommendation for primary prevention should be based on "a complex calculus involving estimates of cardiovascular risk, potentially cancer risk, and bleeding risk," he said.
 
"I do believe that there are patients whose risk calculus is sufficient to warrant aspirin as part of the armamentarium," Gaziano said. "The use of aspirin remains a decision that should involve a thoughtful discussion between the patient and clinician."
 
But given a plethora studies looking at aspirin therapy for CV disease and CV prevention, going back decades, after ARRIVE "I don't think the overall dialog between doctor and patient should change dramatically."
 
Gaziano presented ARRIVE here at the European Society of Cardiology (ESC) 2018 Congress and is lead author on its corresponding publication in the Lancet.
 
The trial reinforces that the decision whether to go on preventive aspirin "should be between the patient and the doctor based on the risk profile of the patient. So it's an individualized decision," agreed Fausto J. Pinto, MD. Pinto, from Lisbon University Medical School, Portugal, who was not involved in the study, made his comment at a briefing on the trial for the media.
 
At the media briefing, Stephan Achenbach, MD, Friedrich-Alexander University, Erlangen-Nuremberg, Germany, agreed that ARRIVE is an endorsement of the individualized approach to considering aspirin in primary prevention.
 
There may be a perception among "informed cardiologists and preventionists" that aspirin has been used "too liberally" in the past, he said. ARRIVE may suggest it's time to view aspirin "in a more individualized fashion, and maybe swing back to being a little more positive about aspirin in primary prevention - if it's done right."
 
Questions Left Unanswered
 
The large randomized trial "ultimately did not address the role of aspirin in patients with at least moderate cardiovascular disease risk, because the study was primarily done with patients at low risk," write Davide Capodanno, MD, Policlinico Vittorio Emanuele, Catania, Sicily, Italy, and Dominick J. Angiolillo, MD, University of Florida College of Medicine, Jacksonville, in an accompanying editorial.
 
Still, "There are important take-home messages from the ARRIVE trial. First, the overall findings replicate those from previous studies testing the use of aspirin for primary prevention in patients at low cardiovascular disease risk," they write.
 
"On the one hand, these study findings reinforce recommendations against the use of aspirin in this setting but, on the other hand, leave unanswered the role of aspirin for primary prevention in patients without diabetes who have at least moderate cardiovascular disease risk."
 
ARRIVE entered 12,546 women at least 60 years old and men at least 55 years old from primary care offices in Germany, Italy, Ireland, Poland, Spain, the United Kingdom, and the United States from July 2007 to November 2016.
 
They were required to have two to four CV risk factors, including dyslipidemia, current smoking, high blood pressure, or a family history of CV disease, regardless of what therapies they might be taking for them. People at high risk of bleeding or with diabetes were excluded.
 
Per Protocol vs ITT
 
Although the ITT analysis represents the trial's primary message, Gaziano said, he and his colleagues made much of a prespecified per protocol analysis conducted on all patients who were at least 60% adherent to their treatment assignment, whether aspirin (n = 3790) or placebo (n = 3912).
 
Even per protocol, aspirin fell short of significance for the composite primary endpoint, at an HR of 0.81 (95% CI, 0.64 - 1.02; P = .076). But there were significant risk reductions for any MI at 0.53 (95% CI, 0.36 - 0.79; P = .0014) and nonfatal of MI 0.55 (95% CI, 0.36 - 0.84; P = .0056).
 
"I'm not relying on the per protocol analysis as a definitive answer. I'm looking at it for some insights as to why the results are somewhat different from a study we know quite well, the Physicians' Health Study," Gaziano said when interviewed.
 
That study from the 1980s, which randomly assigned more than 22,000 health professionals to aspirin at 325 mg every other day or placebo, famously saw a 44% reduction in risk acute MI (P < .00001).
 
Also, after hundreds of aspirin trials, no single additional one will change practice radically, he said; the per protocol analysis will help compare ARRIVE to other studies. "All trials must be interpreted in context with their background, and in this case we have about four decades worth of previous information that we have to integrate."
 
Alex C. Spyropoulos, MD, from Lenox Hill Hospital, New York City, pointed out that a per protocol analysis can make more sense for an aspirin trial than a trial of an unapproved drug. An ITT analysis is the appropriate high standard for testing an agent that is still investigational, but for one that is widely available like aspirin, a per protocol analysis can provide useful insights.
 
"If it's an investigational drug versus one that's readily available, then I think there are different expectations of per protocol vs intention-to-treat," Spyropoulos, who was not involved with ARRIVE, said to theheart.org | Medscape Cardiology.
 
Cleland doesn't seem to buy into the alleged value of a per protocol analysis and sees it as emblematic of a more widespread problem. "The presentation of aspirin data is always biased," he said.
 
"I think it's fine for them to show the per protocol analysis, but ultimately, their conclusions are correct, that there isn't a benefit of aspirin." Or, Cleland added, "that such benefits, if they exist, are so small that, why don't we move on to something more useful."
 
ARRIVE was supported by Bayer. "All voting members of the ARRIVE Executive Committee," which included Gaziano, received fees from Bayer during the study. Disclosures for the other authors are in the report. Capodanno reports receiving speaker's and consulting honoraria from AstraZeneca and Bayer. Angiolillo reports consulting fees or honoraria from Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Janssen, Merck, PLx Pharma, Pfizer, Sanofi, and The Medicines Company; payment for participating in review activities from CeloNova and St Jude Medical; and institutional payments for grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Matsutani Chemical Industry Co, Merck, Novartis, Osprey Medical, and Renal Guard Solutions
 
European Society of Cardiology (ESC) Congress 2018. Lancet. August 26, 2018. Abstract, Editorial
 
---------------------------------
 
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial
 
Discussion
 
In the ARRIVE study, we aimed to address the role of aspirin in primary prevention of cardiovascular disease in patients at moderate risk of a first cardiovascular event, in a pragmatic, primary care-based randomised trial. The findings add important information to the body of evidence and are generally consistent with previous primary prevention studies. This study also showed the challenges of doing long-term primary prevention studies in an era of aggressive management of risk factors among higher-risk individuals.
 
In ARRIVE, aspirin treatment did not lower risk of major cardiovascular events in the enrolled patients, despite the presence of multiple cardiovascular risk factors. Stroke incidence did not differ by treatment group. Similar to other published low-risk primary prevention studies, the risk of myocardial infarction was lower among patients taking aspirin than placebo, but this was not significant; however, this difference was significant in the per-protocol analysis. Of note, none of the p values or secondary endpoints were significant.
 
When determining whether low-dose aspirin is appropriate for an individual patient, the cardiovascular benefit must be weighed against the potential risk for clinical events such as gastrointestinal bleeding (or other bleeds) that can be associated with aspirin use. ARRIVE contributes meaningful clinical information about the risk of bleeding in middle-aged and older patients. The increased risk of gastrointestinal bleeding was in line with what would be expected, because the events were predominantly mild in severity and there was no difference in fatal bleeding rates, consistent with previous primary prevention studies.
 
ARRIVE provides valuable lessons about the challenges of carrying out large-scale primary prevention studies when there are multiple widely available preventive and therapeutic interventions, resulting in lower observed cardiovascular risk than expected. Although the targeted estimated risk for enrolment in ARRIVE was achieved, the observed event rate was considerably less than anticipated. The estimated baseline risk of cardiovascular disease over 10 years, calculated with the American College of Cardiology/American Heart Association risk calculator, was modestly lower than intended, at 17⋅3%. However, the actual rate of cardiovascular disease events, defined by the number of events confirmed in the study (550 vs 1488), was much lower than estimated, at less than 10% over 10 years.
 
There are several possible explanations for this lower actual risk in the ARRIVE population. First, risk calculators developed with older data might overestimate risk in current practice. Second, as a large pragmatic study based in the primary care setting, the ability to obtain records for vascular events was a challenge for some providers that were often remote from the acute care setting. Additionally, patients were only seen for study follow-up once a year after the first year, potentially giving rise to a failure to reliably report temporally distant events. Both of these factors could have led to an undercounting of possible vascular events. Third, cardiovascular risk in a population is not a static feature, and this has been seen in other studies. Patients are being treated for their risk factors to lower the risk of the development of disease. Better management of blood pressure, dyslipidaemia, and other risk factors is likely to lower the risk of developing disease, and these interventions are most aggressively used in patients at higher risk. ARRIVE reflects a contemporary cardiovascular risk prevention (therapy) study in which widespread statin use is the norm. 43% of ARRIVE participants were taking statins. The exclusion of patients with diabetes could also contribute to lower overall risk.
 
Finally, better management of cardiovascular disease when it is manifested by non-acute symptoms can reduce the risk of major acute events. If a patient develops stable angina and receives more intense management including non-study aspirin and close follow-up, the chance of developing a myocardial infarction or other cardiovascular disease event is lessened. This finding is suggested by the difference between the intention-to-treat and per-protocol analyses, particularly for myocardial infarction. It is also supported by the suggestion of a bigger effect early in the study, compared with later in the study. ARRIVE sought to further assess the effects of aspirin on cancer outcomes during the study. However, the ARRIVE study duration was probably not sufficient to investigate cancer outcomes and to rule out the possibility of benefits of aspirin on long-term cancer outcomes; hence the ARRIVE study could not add information in this regard. Results about incidence of all cancers will be reported elsewhere.
 
Although the absolute event rates in ARRIVE were lower than expected, the relative effects on specific outcomes were generally similar to those in previous studies in primary prevention of vascular events. Meta-analyses of previous studies showed that aspirin reduces risk of non-fatal myocardial infarction and all myocardial infarction, but does not reduce total stroke or all-cause vascular death.22
 
The results of ARRIVE, which suggested a stronger effect of aspirin early in the study, compared with later in the study, are also consistent with previous analyses of the time-course of effects of daily aspirin on risk of major vascular events in randomised studies. Whether this atrophy of benefit would be seen in routine practice, when patients know that they are taking active drug rather than placebo, is unknown but it could be argued that in studies with high rates of discontinuation of study treatment, the effects of aspirin during the first 3 years of follow-up provide the best estimate of the probable effects in routine practice in patients who take the drug.
 
A strength of the ARRIVE study was the inclusion of a large number of older individuals and women with risk of cardiovascular disease. The study was a pragmatic study done in the primary care setting. As such, it was challenging to identify a population at true moderate risk throughout the long treatment period, given the preventive and therapeutic care participants were receiving, thereby reducing the overall power of the study to detect an effect on the primary outcome. Furthermore, it was challenging to capture all efficacy and safety events in this setting.
 
Compliance represents another major challenge in contemporaneous studies given the ongoing discussions about aspirin among providers, patients, and the public. By contrast with the null finding for the intention-to-treat analysis, the significant treatment differences observed in the per-protocol analysis (ie, approximately 60% of the study population; n=7702) suggests that compliance played a role. During the study, it appears that there was an impact of discussions about the use of aspirin in clinical practice in UK. In the UK subset, results seemed to be different from the rest of the study population, possibly reflecting coverage in the UK medical and general news media after 2009, regarding uncertainty about the effectiveness of aspirin in primary prevention.2
 
High rates of discontinuation of study treatment in the UK subset of the study are consistent with this possibility.
 
Another related compliance issue was the potential use of aspirin by patients who became higher risk during the study. For example, if a patient developed chest pain or had a transient ischaemic event, they might well have been withdrawn from the study and started taking aspirin. To address this issue, the Executive Committee amended the protocol to add transient ischaemic events and unstable angina to the primary endpoint, given that these are two conditions biologically related to the primary composite endpoint, and for which clinicians would probably have selectively withdrawn the affected patient from the study. Redefinition of the primary composite endpoint is a strategy that has been used in other contemporary studies to link biologically related primary endpoints, compensate for selective withdrawals, and increase the number of primary endpoints. However, the results of the redefined primary endpoint were not different from those of the original primary endpoint.
 
While ARRIVE attempted to add relevant information about the cardiovascular benefits and bleeding risks of aspirin in patients at moderate cardiovascular risk, it showed some of the challenges in doing long-term prevention studies in the current era. ARRIVE is generally consistent with many other studies that show aspirin's ability to lower the risk of first non-fatal myocardial infarction without affecting risk of total stroke. With respect to safety, as expected, rates of gastrointestinal bleeding events and some other minor bleeding events were higher in the aspirin treatment group, but there was no significant difference in the incidence of fatal events.
 
The use of aspirin remains a decision that should involve a thoughtful discussion between a clinician and a patient, given the need to weigh cardiovascular and possible cancer prevention benefits against the bleeding risks, patient preferences, cost, and other factors. The ARRIVE data must be interpreted and used in the context of other studies, which have tended to show a reduction primarily in myocardial infarction, with less of an effect on total stroke (including both ischaemic and haemorrhagic stroke). The overall decision to use aspirin for cardiovascular effects should be done with the help a clinician, given the complex calculus needed to balance all potential benefits and risks.
 
Summary
 
Background

 
The use of aspirin in the primary prevention of cardiovascular events remains controversial. We aimed to assess the efficacy and safety of aspirin versus placebo in patients with a moderate estimated risk of a first cardiovascular event.
 
Methods
 
ARRIVE is a randomised, double-blind, placebo-controlled, multicentre study done in seven countries. Eligible patients were aged 55 years (men) or 60 years (women) and older and had an average cardiovascular risk, deemed to be moderate on the basis of the number of specific risk factors. We excluded patients at high risk of gastrointestinal bleeding or other bleeding, or diabetes. Patients were randomly assigned (1:1) with a computer-generated randomisation code to receive enteric-coated aspirin tablets (100 mg) or placebo tablets, once daily. Patients, investigators, and others involved in treatment or data analysis were masked to treatment allocation. The primary efficacy endpoint was a composite outcome of time to first occurrence of cardiovascular death, myocardial infarction, unstable angina, stroke, or transient ischaemic attack. Safety endpoints were haemorrhagic events and incidence of other adverse events, and were analysed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00501059.
 
Findings
 
Between July 5, 2007, and Nov 15, 2016, 12 546 patients were enrolled and randomly assigned to receive aspirin (n=6270) or placebo (n=6276) at 501 study sites. Median follow-up was 60 months. In the intention-to-treat analysis, the primary endpoint occurred in 269 (4⋅29%) patients in the aspirin group versus 281 (4⋅48%) patients in the placebo group (hazard ratio [HR] 0⋅96; 95% CI 0⋅81-1⋅13; p=0⋅6038). Gastrointestinal bleeding events (mostly mild) occurred in 61 (0⋅97%) patients in the aspirin group versus 29 (0⋅46%) in the placebo group (HR 2⋅11; 95% CI 1⋅36-3⋅28; p=0⋅0007). The overall incidence rate of serious adverse events was similar in both treatment groups (n=1266 [20⋅19%] in the aspirin group vsn=1311 [20⋅89%] in the placebo group. The overall incidence of adverse events was similar in both treatment groups (n=5142 [82⋅01%] vs n=5129 [81⋅72%] in the placebo group). The overall incidence of treatment-related adverse events was low (n=1050 [16⋅75%] vs n=850 [13⋅54%] in the placebo group; p<0⋅0001). There were 321 documented deaths in the intention-to-treat population (n=160 [2⋅55%] vs n=161 [2⋅57%] of 6276 patients in the placebo group).
 
Interpretation
 
The event rate was much lower than expected, which is probably reflective of contemporary risk management strategies, making the study more representative of a low-risk population. The role of aspirin in primary prevention among patients at moderate risk could therefore not be addressed. Nonetheless, the findings with respect to aspirin's effects are consistent with those observed in the previously published low-risk primary prevention studies.
 
Funding
 
Bayer.
 
--------------------------------------------------------
 
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus - [75% were on statin]....also is study looking at n−3 fatty acids, also in diabetics with 75% using a statin, adherence was 77%
 
Aug 26 2018 NEJM
 
The ASCEND Study Collaborative Group
 
Abstract
 
Background

 
Diabetes mellitus is associated with an increased risk of cardiovascular events. Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear.
 
Methods
 
We randomly assigned adults who had diabetes but no evident cardiovascular disease to receive aspirin at a dose of 100 mg daily or matching placebo. The primary efficacy outcome was the first serious vascular event (i.e., myocardial infarction, stroke or transient ischemic attack, or death from any vascular cause, excluding any confirmed intracranial hemorrhage). The primary safety outcome was the first major bleeding event (i.e., intracranial hemorrhage, sight-threatening bleeding event in the eye, gastrointestinal bleeding, or other serious bleeding). Secondary outcomes included gastrointestinal tract cancer.
 
Using minimized randomization, we then assigned eligible participants to receive 100 mg of aspirin once daily or a matching placebo tablet16; participants were also assigned to receive 1-g capsules containing n−3 fatty acid once daily or a matching placebo capsule. The participants were then mailed a 6-month supply of aspirin or placebo tablets and n−3 fatty acids or placebo capsules, as appropriate.
 
Results
 
A total of 15,480 participants underwent randomization. During a mean follow-up of 7.4 years, serious vascular events occurred in a significantly lower percentage of participants in the aspirin group than in the placebo group (658 participants [8.5%] vs. 743 [9.6%]; rate ratio, 0.88; 95% confidence interval [CI], 0.79 to 0.97; P=0.01). In contrast, major bleeding events occurred in 314 participants (4.1%) in the aspirin group, as compared with 245 (3.2%) in the placebo group (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), with most of the excess being gastrointestinal bleeding and other extracranial bleeding. There was no significant difference between the aspirin group and the placebo group in the incidence of gastrointestinal tract cancer (157 participants [2.0%] and 158 [2.0%], respectively) or all cancers (897 [11.6%] and 887 [11.5%]); long-term follow-up for these outcomes is planned.
 
Conclusions
 
Aspirin use prevented serious vascular events in persons who had diabetes and no evident cardiovascular disease at trial entry, but it also caused major bleeding events. The absolute benefits were largely counterbalanced by the bleeding hazard.
(Funded by the British Heart Foundation and others; ASCEND
 
Outcomes
 
While recruitment was still ongoing, we modified the original primary outcome to include transient ischemic attack in the definition of serious vascular event, a change that was made to increase the statistical power of the trial. Thus, the prespecified primary efficacy outcome was the first serious vascular event, which was defined as a composite of nonfatal myocardial infarction, nonfatal stroke (excluding confirmed intracranial hemorrhage) or transient ischemic attack, or death from any vascular cause (excluding confirmed intracranial hemorrhage). The primary safety outcome was the first occurrence of any major bleeding event, which was defined as a composite of any confirmed intracranial hemorrhage, sight-threatening bleeding event in the eye, gastrointestinal bleeding, or any other serious bleeding (i.e., a bleeding event that resulted in hospitalization or transfusion or that was fatal). Secondary outcomes were gastrointestinal tract cancer (overall and excluding those occurring during the first 3 years of follow-up) and the composite of any serious vascular event or any arterial revascularization procedure. All the reports of possible primary or secondary outcomes were adjudicated centrally by clinicians who were unaware of the trial-group assignments in accordance with prespecified definitions. The data analysis plan prespecified that analyses would be based on all the confirmed events plus unrefuted events (see the Methods section in Supplementary Appendix 1).
 
It is well established that aspirin use is beneficial for patients with cardiovascular disease, but it is less clear that there is overall benefit in persons who have not yet had a cardiovascular event.1,2 Patients with diabetes mellitus have a risk of vascular events that is two to three times as high as the risk among those without diabetes,3 but most of the estimated 400 million persons with diabetes worldwide do not have manifest vascular disease.4
 
The 2009 Antithrombotic Trialists' Collaboration meta-analysis involving 95,000 patients in six primary prevention trials showed that assignment to aspirin use led to a 12% (95% confidence interval [CI], 6 to 18) lower risk of serious vascular events than control.1 On average, however, the approximate 50% higher risk of bleeding with aspirin use than with control counterbalanced much of the benefit in these low-risk patients. Only approximately 4% of participants in those trials had diabetes, and the lower relative risk among them was similar to that observed among participants without diabetes (as was also observed in the context of secondary prevention). Likewise, the higher relative risk of bleeding with aspirin use than with control was similar among persons with diabetes and those without diabetes.
 
Since the analyses of the Antithrombotic Trialists' Collaboration, four trials of aspirin use for primary prevention (two specifically involving patients with diabetes5,6 and two in broader populations7,8) have been reported; none showed a clear benefit or reported detailed information regarding bleeding events, so the balance of benefits and risks associated with aspirin use for primary prevention among persons with diabetes remains uncertain. Partly as a result of these studies, there has been speculation that diabetes may be associated with reduced efficacy of the antiplatelet effects of aspirin.9
 
Retrospective meta-analyses of selected randomized trials of mainly low-dose aspirin have suggested that aspirin use may result in an incidence of cancer or death from cancer that is 15 to 20% lower than that with control.10-13 In particular, reductions of 30 to 40% in the incidence of gastrointestinal cancers (particularly colorectal cancer) were observed, with the effects appearing to increase with more prolonged exposure and with longer follow-up up to 20 years. Data from randomized trials of sufficient size and duration will be useful in assessing any effects of aspirin use on cancer more reliably. We performed the ASCEND (A Study of Cardiovascular Events in Diabetes) randomized trial to assess the efficacy and safety of enteric-coated aspirin at a dose of 100 mg daily, as compared with placebo, in persons who had diabetes without manifest cardiovascular disease at trial entry. Using a factorial design in the same trial, we also randomly assigned the patients to receive a daily regimen of either n−3 fatty acids, administered as 1-g capsules, or placebo, findings that are now reported elsewhere in the Journal.14
 
Discussion
 
In this trial involving persons who had diabetes without manifest cardiovascular disease, assignment to the use of aspirin at a dose of 100 mg daily for 7.4 years resulted in a risk of serious vascular events that was 12% lower than that with placebo but also in a risk of major bleeding that was 29% higher. The lower risk of serious vascular events is similar to the risk that was reported previously in the Antithrombotic Trialists' Collaboration meta-analysis of primary prevention trials of similar doses of aspirin (which used slightly different outcome definitions; see the Methods section in Supplementary Appendix 1).1 In contrast to those previous trials, there were high rates of the use of cardioprotective treatments among the participants in ASCEND, with the majority of participants taking statins and blood pressure-lowering therapy. Hence, the present trial provides a direct assessment of the balance of the benefits and hazards of aspirin use in a contemporary context.
 
In our trial, factors such as the large number of participants and clinical outcomes, long duration of follow-up, the randomized, blinded design of the trial, and the almost complete follow-up of the participants who underwent randomization have allowed reliable detection of these moderate but important effects on the incidence of vascular events and on both the severity and incidence of bleeding. Our findings do not support the hypothesis that persons with diabetes have a resistance to aspirin.9Although the proportional effects of aspirin use are likely to be generalizable to the wider population of persons with diabetes, the absolute event rates and adherence rates reflect this population of persons with well-treated diabetes. Overall, on the basis of the absolute percentage differences between the groups in the incidence of serious vascular events (1.1 percentage points lower in the aspirin group than in the placebo group) and in bleeding events (0.9 percentage points higher in the aspirin group), 91 patients would need to be treated to avoid a serious vascular event over a period of 7.4 years, and 112 to cause a major bleeding event.
 
These results of intention-to-treat analyses tend to underestimate the effect of actual aspirin use, both with respect to events avoided and bleeding events caused owing to a lack of full adherence to the regimen during the trial. Exploratory analyses comparing participants at different levels of vascular risk extrapolated the rate ratios in the intention-to-treat analysis to full adherence and assumed that the proportional effects on the incidence of serious vascular events and bleeding were the same across different levels of vascular risk. The results of these analyses provide a more reliable estimate of the absolute differences in the event rates resulting from aspirin use by applying the extrapolated overall rate ratios to the event rates with placebo in each risk group. On the basis of these assumptions, the predicted number of serious vascular events that would be avoided by participants actually taking aspirin was closely balanced by the predicted number of major bleeding events caused, even among persons who had a 5-year vascular risk of 10% or more (Fig. S6 in Supplementary Appendix 1). A recent analysis suggesting a greater benefit of low-dose aspirin use on the incidence of vascular events among persons with a body weight of less than 70 kg was not confirmed in exploratory subgroup analyses (and, indeed, a trend in the opposite direction was observed).19
 
The assessment of the balance between the benefit and harm of aspirin use in the context of primary prevention is complicated by the difficulty of comparing the severity of the vascular events avoided and the bleeding events caused. For example, although transient ischemic attacks are minor in themselves, they are associated with increased risks of subsequent stroke and cognitive impairment.20 Approximately half the excess of bleeding was in the gastrointestinal tract, with approximately one third in the upper gastrointestinal tract. However, even near the end of the trial in 2016, only approximately one quarter of participants were receiving proton-pump inhibitors (PPIs). It is possible that bleeding rates among aspirin users might be lower if PPIs were routinely used in these persons, provided that longer-term trials of PPIs21,22 confirm the substantial reductions in the incidence of bleeding in the upper gastrointestinal tract that has been seen in short-term studies,23 as well as confirming long-term safety. Several meta-analyses of selected randomized trials of generally low-dose aspirin have suggested that aspirin use might reduce the risk of cancer - in particular, gastrointestinal tract cancer - by up to one third during long-term follow-up, with effects becoming apparent approximately 3 years after randomization.10,12,13,24 However, despite more than 7 years of aspirin treatment and follow-up in ASCEND, we found no evidence of a reduction in the incidence of gastrointestinal tract cancer or of cancer at any other site, even during the later years of follow-up. These analyses had limited statistical power to detect the hypothesized effects, so follow-up is being continued through central registries.
 
In conclusion, the use of low-dose aspirin led to a lower risk of serious vascular events than placebo among persons with diabetes who did not have evident cardiovascular disease at trial entry. However, the absolute lower rates of serious vascular events were of similar magnitude to the absolute higher rates of major bleeding, even among participants who had a high vascular risk. The use of low-dose aspirin did not result in a lower risk of gastrointestinal tract cancer or other cancer over the mean follow-up of 7.4 years, but further follow-up is needed to assess any longer-term effects on cancer reliably.
 
_______ 


 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org